A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinectics of PLN-74809 in participants with idiopathic pulmonary fibrosis.
- Glaspole, Ian (Primary Chief Investigator (PCI))
- Symons, Karen M. (Project Manager)
- Corte, Tamera Jo (Chief Investigator (CI))
Project: Research